HC Wainwright & Co. Reiterates Buy on Barinthus Biotherapeutics, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Barinthus Biotherapeutics (NASDAQ:BRNS) and maintained a price target of $8.
June 07, 2024 | 3:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Barinthus Biotherapeutics and maintained a price target of $8.
The reiteration of a Buy rating and the maintenance of a price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100